Financials data is unavailable for this security.
View more
Year on year Xiamen Amoytop Biotech Co Ltd grew revenues 37.55% from 1.53bn to 2.10bn while net income improved 93.52% from 287.02m to 555.45m.
| Gross margin | 92.97% |
|---|---|
| Net profit margin | 27.55% |
| Operating margin | 33.41% |
| Return on assets | 30.81% |
|---|---|
| Return on equity | 37.18% |
| Return on investment | 35.47% |
More ▼
Cash flow in CNYView more
In 2023, Xiamen Amoytop Biotech Co Ltd increased its cash reserves by 37.40%, or 112.32m. The company earned 512.10m from its operations for a Cash Flow Margin of 24.38%. In addition the company used 305.76m on investing activities and also paid 92.91m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.95 |
|---|---|
| Tangible book value per share | 4.07 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.07 |
|---|---|
| Quick ratio | 3.34 |
| Total debt/total equity | 0.0051 |
|---|---|
| Total debt/total capital | 0.005 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 92.49% and 93.52%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth ranks highest in its industry.
| Div yield(5 year avg) | 0.36% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 25.36% |
| EPS growth(5 years) | 98.40 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 84.96 |
More ▼
